OBJECTIVES: We tested whether serum soluble lectin-like oxidized low-density lipoprotein receptor-1 (sLOX-1) levels are able to predict in-stent restenosis (ISR) after successful primary percutaneous coronary intervention (PCI). METHODS: Preprocedural and postprocedural serum sLOX-1 levels were measured in 210 consecutive patients with stable coronary artery disease who underwent successful primary PCI for de novo lesions. The patients were grouped as ISR and non-ISR based on angiographic follow-up results. RESULTS: PCI significantly increased serum sLOX-1 levels both in patients with [0.85 (range: 0.63-0.98) vs. 0.39 (range: 0.27-0.54) ng/ml, P < 0.01] or without ISR [0.45 (range: 0.36-0.84) vs. 0.32 (range: 0.28-0.62) ng/ml, P < 0.01]. Postprocedural serum sLOX-1 levels were higher in patients with ISR than those without ISR [0.85 (range: 0.63-0.98) vs. 0.45 (range: 0.36-0.84) ng/ml, P < 0.01]. High postprocedural serum sLOX-1 levels served as independent predictors of ISR (odds ratio: 3.040, 95% confidence interval: 1.359-6.802, P < 0.01). Furthermore, postprocedural serum sLOX-1 levels were correlated with late lumen loss of the stented lesions (ρ = 0.36, P < 0.01). CONCLUSION: Postprocedural serum sLOX-1 levels are significantly associated with the risk of ISR and the severity of lumen loss in patients with stable coronary artery disease undergoing primary PCI. These results suggested that postprocedural serum sLOX-1 levels might be useful for the detection and risk assessment of ISR after PCI.
OBJECTIVES: We tested whether serum soluble lectin-like oxidized low-density lipoprotein receptor-1 (sLOX-1) levels are able to predict in-stent restenosis (ISR) after successful primary percutaneous coronary intervention (PCI). METHODS: Preprocedural and postprocedural serum sLOX-1 levels were measured in 210 consecutive patients with stable coronary artery disease who underwent successful primary PCI for de novo lesions. The patients were grouped as ISR and non-ISR based on angiographic follow-up results. RESULTS: PCI significantly increased serum sLOX-1 levels both in patients with [0.85 (range: 0.63-0.98) vs. 0.39 (range: 0.27-0.54) ng/ml, P < 0.01] or without ISR [0.45 (range: 0.36-0.84) vs. 0.32 (range: 0.28-0.62) ng/ml, P < 0.01]. Postprocedural serum sLOX-1 levels were higher in patients with ISR than those without ISR [0.85 (range: 0.63-0.98) vs. 0.45 (range: 0.36-0.84) ng/ml, P < 0.01]. High postprocedural serum sLOX-1 levels served as independent predictors of ISR (odds ratio: 3.040, 95% confidence interval: 1.359-6.802, P < 0.01). Furthermore, postprocedural serum sLOX-1 levels were correlated with late lumen loss of the stented lesions (ρ = 0.36, P < 0.01). CONCLUSION: Postprocedural serum sLOX-1 levels are significantly associated with the risk of ISR and the severity of lumen loss in patients with stable coronary artery disease undergoing primary PCI. These results suggested that postprocedural serum sLOX-1 levels might be useful for the detection and risk assessment of ISR after PCI.
Authors: Ilker Murat Caglar; Cem Ozde; Ismail Biyik; Fatma Nihan Turhan Caglar; Ibrahim Faruk Akturk; Murat Ugurlucan; Osman Karakaya Journal: Arch Med Sci Date: 2016-02-02 Impact factor: 3.318
Authors: Katharine A Kott; Michael Bishop; Christina H J Yang; Toby M Plasto; Daniel C Cheng; Adam I Kaplan; Louise Cullen; David S Celermajer; Peter J Meikle; Stephen T Vernon; Gemma A Figtree Journal: Cells Date: 2022-02-08 Impact factor: 6.600